{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:12Z","timestamp":1792801932074,"version":"4.5.0"},"reference-count":88,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc","id":[{"id":"https:\/\/ror.org\/02ha0t079","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patient responses to medical therapy for acromegaly are variable. Adenoma features, including histologic characteristics and receptor density, are closely associated with distinct clinical behavior and therapeutic outcomes. Densely granulated pure somatotropinomas respond more favorably to somatostatin receptor subtype 2 (SST2)-selective ligands (octreotide and lanreotide) compared with sparsely granulated adenomas. In contrast, sparsely granulated adenomas may respond more favorably to pasireotide, which has a higher affinity for somatostatin receptor subtype 5 (SST5). Expression levels of SST2 receptors are also associated with responsiveness to octreotide and lanreotide, whereas response to pasireotide is linked to higher SST5 expression. Recent prospective studies have highlighted that treatment strategies guided by biomarkers determining therapeutic response are more effective than standard, non\u2013biomarker-based approaches. Current evidence supports the incorporation of biomarkers into decision-making for medical management of acromegaly, while these approaches are being further validated.<\/jats:p>","DOI":"10.1210\/clinem\/dgag180","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:50:56Z","timestamp":1776858656000},"page":"S77-S88","source":"Crossref","is-referenced-by-count":2,"title":["Adenoma receptors and histologic characteristics determining management outcomes"],"prefix":"10.1210","volume":"111","author":[{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"first","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School, and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]},{"name":"Neuroendocrine Unit, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M\u00f4nica R","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School, and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]},{"name":"Neuroendocrine Unit, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 ,","place":["Brazil"]},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"3","key":"2026060416140526000_dgag180-B1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr Rev"},{"issue":"6","key":"2026060416140526000_dgag180-B2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11102-023-01353-0","article-title":"Clinical and prognostic significance of granulation patterns in somatotroph adenomas\/tumors of the pituitary: a meta-analysis","volume":"26","author":"Vuong","year":"2023","journal-title":"Pituitary"},{"issue":"4","key":"2026060416140526000_dgag180-B3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416140526000_dgag180-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2026060416140526000_dgag180-B5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416140526000_dgag180-B6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","volume":"46","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"key":"2026060416140526000_dgag180-B7","volume-title":"Endocrine and Neuroendocrine Tumours","year":"2022","edition":"5th ed"},{"issue":"2","key":"2026060416140526000_dgag180-B8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026060416140526000_dgag180-B9","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13302","article-title":"The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors","volume":"35","author":"Casar-Borota","year":"2025","journal-title":"Brain Pathol"},{"issue":"19","key":"2026060416140526000_dgag180-B10","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"Gadelha MR. gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026060416140526000_dgag180-B11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"issue":"11","key":"2026060416140526000_dgag180-B12","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416140526000_dgag180-B13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"issue":"4","key":"2026060416140526000_dgag180-B14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416140526000_dgag180-B15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"key":"2026060416140526000_dgag180-B16","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/j.wneu.2024.02.115","article-title":"Clinicopathological analysis of densely and sparsely granulated somatotroph tumors of pituitary","volume":"185","author":"Wang","year":"2024","journal-title":"World Neurosurg"},{"issue":"4","key":"2026060416140526000_dgag180-B17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"1","key":"2026060416140526000_dgag180-B18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026060416140526000_dgag180-B19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.957301","article-title":"Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026060416140526000_dgag180-B20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12902-021-00850-2","article-title":"Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study","volume":"21","author":"Dehghani","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2026060416140526000_dgag180-B21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-0033-1354578","article-title":"Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly","volume":"75","author":"Sun","year":"2014","journal-title":"J Neurol Surg B Skull Base"},{"issue":"7","key":"2026060416140526000_dgag180-B22","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416140526000_dgag180-B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"2026060416140526000_dgag180-B24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","article-title":"Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas","volume":"59","author":"Kato","year":"2012","journal-title":"Endocr J"},{"issue":"2","key":"2026060416140526000_dgag180-B25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026060416140526000_dgag180-B26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect"},{"issue":"16","key":"2026060416140526000_dgag180-B27","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.3390\/ijms25168663","article-title":"Predicting response to medical treatment in acromegaly via granulation pattern, expression of somatostatin receptors type 2 and 5 and E-cadherin","volume":"25","author":"Gliga","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026060416140526000_dgag180-B28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1210\/clinem\/dgaf634","article-title":"Clinical and pathological Spectrum of acromegaly: distinguishing GH-PitNETs, mammosomatotrophs and mixed tumors","volume":"111","author":"Martinez-Hernandez","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2026060416140526000_dgag180-B29","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.3390\/ijms241814002","article-title":"Prolactin and growth hormone signaling and interlink focused on the mammosomatotroph paradigm: a comprehensive review of the literature","volume":"24","author":"Araujo-Castro","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026060416140526000_dgag180-B30","doi-asserted-by":"crossref","first-page":"e2178","DOI":"10.1210\/clinem\/dgae126","article-title":"Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases","volume":"109","author":"Araujo-Castro","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416140526000_dgag180-B31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12020-019-02029-1","article-title":"Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up","volume":"66","author":"Lv","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"2026060416140526000_dgag180-B32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ejendo\/lvae003","article-title":"Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study","volume":"190","author":"Urwyler","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416140526000_dgag180-B33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3171\/2018.4.JNS18230","article-title":"Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes","volume":"131","author":"Rick","year":"2018","journal-title":"J Neurosurg"},{"issue":"2","key":"2026060416140526000_dgag180-B34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416140526000_dgag180-B35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416140526000_dgag180-B36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2004.02082.x","article-title":"Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status","volume":"61","author":"Cozzi","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416140526000_dgag180-B37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000218323","article-title":"Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide","volume":"90","author":"Jallad","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2026060416140526000_dgag180-B38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly","volume":"92","author":"Mattar","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2026060416140526000_dgag180-B39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"2026060416140526000_dgag180-B40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda","year":"2013","journal-title":"Endocr J"},{"issue":"9","key":"2026060416140526000_dgag180-B41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/a-1274-1276","article-title":"Effectiveness of cabergoline treatment in patients with acromegaly uncontrolled with SSAs: experience of a single tertiary center","volume":"129","author":"Sahin","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2026060416140526000_dgag180-B42","first-page":"278","article-title":"Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature","volume":"66","author":"Kizilgul","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"2026060416140526000_dgag180-B43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ejendo\/lvae053","article-title":"Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion","volume":"190","author":"Biagetti","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416140526000_dgag180-B44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11102-025-01556-7","article-title":"Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenoma","volume":"28","author":"Rajan","year":"2025","journal-title":"Pituitary"},{"key":"2026060416140526000_dgag180-B45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1571598","article-title":"Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly","volume":"16","author":"Chong","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026060416140526000_dgag180-B46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00401-024-02686-1","article-title":"Pituitary neuroendocrine tumors with PIT1\/SF1 co-expression show distinct clinicopathological and molecular features","volume":"147","author":"Dottermusch","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2026060416140526000_dgag180-B47","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1210\/clinem\/dgae262","article-title":"GH and prolactin co-secreting adenomas: it is time for a definition","volume":"110","author":"Wildemberg","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416140526000_dgag180-B48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/endrev\/bnae022","article-title":"Structure and function of somatostatin and its receptors in endocrinology","volume":"46","author":"Zhang","year":"2025","journal-title":"Endocr Rev"},{"issue":"1","key":"2026060416140526000_dgag180-B49","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13313","article-title":"Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: a pathologist's perspective","volume":"35","author":"Botelho","year":"2025","journal-title":"Brain Pathol"},{"issue":"8","key":"2026060416140526000_dgag180-B50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","article-title":"Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues","volume":"120","author":"Unger","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2026060416140526000_dgag180-B51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026060416140526000_dgag180-B52","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416140526000_dgag180-B53","first-page":"580","article-title":"Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry","volume":"35","author":"Wildemberg","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026060416140526000_dgag180-B54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humpath.2013.08.007","article-title":"Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies","volume":"45","author":"Chinezu","year":"2014","journal-title":"Hum Pathol"},{"issue":"2","key":"2026060416140526000_dgag180-B55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","article-title":"Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting","volume":"36","author":"Korner","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2026060416140526000_dgag180-B56","doi-asserted-by":"crossref","first-page":"e4382","DOI":"10.1210\/clinem\/dgac584","article-title":"Routine evaluation of somatostatin receptor type 2 in patients with acromegaly: do we still need more evidence?","volume":"107","author":"Gatto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416140526000_dgag180-B57","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416140526000_dgag180-B58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-22-0339","article-title":"Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study","volume":"187","author":"Campana","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416140526000_dgag180-B59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2026060416140526000_dgag180-B60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416140526000_dgag180-B61","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416140526000_dgag180-B62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12022-007-9004-0","article-title":"Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide","volume":"18","author":"Takei","year":"2007","journal-title":"Endocr Pathol"},{"issue":"4","key":"2026060416140526000_dgag180-B63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Plockinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416140526000_dgag180-B64","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416140526000_dgag180-B65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"},{"issue":"3","key":"2026060416140526000_dgag180-B66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416140526000_dgag180-B67","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026060416140526000_dgag180-B68","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416140526000_dgag180-B69","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"key":"2026060416140526000_dgag180-B70","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9606985","article-title":"Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2026060416140526000_dgag180-B71","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41598-018-37692-3","article-title":"Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles","volume":"9","author":"Coelho","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"2026060416140526000_dgag180-B72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026060416140526000_dgag180-B73","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly-a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416140526000_dgag180-B74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04620-7","article-title":"Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in acromegaly","volume":"167","author":"Luo","year":"2024","journal-title":"J Neurooncol"},{"issue":"1","key":"2026060416140526000_dgag180-B75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026060416140526000_dgag180-B76","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102924","article-title":"Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly","volume":"54","author":"Marques-Pamies","year":"2023","journal-title":"Arch Med Res"},{"issue":"8","key":"2026060416140526000_dgag180-B77","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1590\/S0004-27302008000800014","article-title":"Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly","volume":"52","author":"Neto L","year":"2008","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"2026060416140526000_dgag180-B78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026060416140526000_dgag180-B79","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1068061","article-title":"Molecular targets in acromegaly","volume":"13","author":"Labadzhyan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026060416140526000_dgag180-B80","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416140526000_dgag180-B81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416140526000_dgag180-B82","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary"},{"issue":"2","key":"2026060416140526000_dgag180-B83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1210\/clinem\/dgaf375","article-title":"Integrative machine learning approach for predicting resistance to first-generation receptor ligands in acromegaly","volume":"111","author":"Lin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416140526000_dgag180-B84","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11102-022-01216-0","article-title":"Machine learning as a clinical decision support tool for patients with acromegaly","volume":"25","author":"Sulu","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"2026060416140526000_dgag180-B85","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"2026060416140526000_dgag180-B86","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"issue":"1","key":"2026060416140526000_dgag180-B87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060416140526000_dgag180-B88","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag180\/68155856\/dgag180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S77\/68155856\/dgag180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S77\/68155856\/dgag180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:14:21Z","timestamp":1780604061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S77\/8662074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":88,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag180","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,24]]}}}